Lee Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Lee Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-68	Closed	-$59.7K	–	661
2023 Q4	$59.7K	Buy	68 +6	+10%	+$4.94K	0.01%	215
2023 Q3	$51K	Hold	62	–	–	0.01%	216
2023 Q2	$44.6K	Hold	62	–	–	0.01%	231
2023 Q1	$50.9K	Hold	62	–	–	0.01%	228
2022 Q4	$44.7K	Hold	62	–	–	0.01%	261
2022 Q3	$42K	Buy	62 +1	+2%	+$629	0.01%	264
2022 Q2	$36K	Sell	61 -2	-3%	-$1.3K	0.01%	270
2022 Q1	$44K	Buy	63 +41	+186%	+$25.9K	0.01%	250
2021 Q4	$14K	Hold	22	–	–	﹤0.01%	432
2021 Q3	$13K	Hold	22	–	–	﹤0.01%	397
2021 Q2	$12K	Hold	22	–	–	﹤0.01%	384
2021 Q1	$10K	Hold	22	–	–	﹤0.01%	387
2020 Q4	$11K	Hold	22	–	–	﹤0.01%	367
2020 Q3	$12K	Hold	22	–	–	﹤0.01%	380
2020 Q2	$14K	Hold	22	–	–	﹤0.01%	321
2020 Q1	$11K	Hold	22	–	–	﹤0.01%	287
2019 Q4	$8K	Hold	22	–	–	﹤0.01%	383
2019 Q3	$6K	Hold	22	–	–	﹤0.01%	411
2019 Q2	$7K	Buy	+22	New	+$7.32K	﹤0.01%	408

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Lee Financial's REGN Position: Q1 2024 in Review

Lee Financial sold out of Regeneron Pharmaceuticals (REGN) in Q1 2024, closing a stake of 68 shares — an estimated $59.7K sold.

Lee Financial first reported a position in REGN in Q2 2019 and held it in 19 quarters. The position peaked at $59.7K in Q4 2023. 1,312 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Lee Financial reported no remaining Regeneron Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Lee Financial sold 68 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $59.7K.
Lee Financial first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 19 quarters.
Lee Financial's Regeneron Pharmaceuticals position peaked at $59.7K in Q4 2023.
1,312 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Lee Financial's 13F filing for Q1 2024, filed 15 May 2024.